JP2017527274A5 - - Google Patents

Download PDF

Info

Publication number
JP2017527274A5
JP2017527274A5 JP2017504103A JP2017504103A JP2017527274A5 JP 2017527274 A5 JP2017527274 A5 JP 2017527274A5 JP 2017504103 A JP2017504103 A JP 2017504103A JP 2017504103 A JP2017504103 A JP 2017504103A JP 2017527274 A5 JP2017527274 A5 JP 2017527274A5
Authority
JP
Japan
Prior art keywords
binding molecule
seq
sequence
bispecific binding
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017504103A
Other languages
English (en)
Japanese (ja)
Other versions
JP6871155B2 (ja
JP2017527274A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/041989 external-priority patent/WO2016014942A1/en
Publication of JP2017527274A publication Critical patent/JP2017527274A/ja
Publication of JP2017527274A5 publication Critical patent/JP2017527274A5/ja
Application granted granted Critical
Publication of JP6871155B2 publication Critical patent/JP6871155B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017504103A 2014-07-25 2015-07-24 二重特異性her2及びcd3結合分子 Active JP6871155B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462029342P 2014-07-25 2014-07-25
US62/029,342 2014-07-25
PCT/US2015/041989 WO2016014942A1 (en) 2014-07-25 2015-07-24 Bispecific her2 and cd3 binding molecules

Publications (3)

Publication Number Publication Date
JP2017527274A JP2017527274A (ja) 2017-09-21
JP2017527274A5 true JP2017527274A5 (show.php) 2018-10-18
JP6871155B2 JP6871155B2 (ja) 2021-05-12

Family

ID=53836217

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017504103A Active JP6871155B2 (ja) 2014-07-25 2015-07-24 二重特異性her2及びcd3結合分子

Country Status (15)

Country Link
US (2) US10519248B2 (show.php)
EP (1) EP3172236B1 (show.php)
JP (1) JP6871155B2 (show.php)
KR (1) KR102638104B1 (show.php)
CN (1) CN107124884B (show.php)
AU (1) AU2015292374B2 (show.php)
BR (1) BR112017001513A2 (show.php)
CA (1) CA2956014C (show.php)
ES (1) ES2832704T3 (show.php)
IL (1) IL250249B (show.php)
MX (1) MX386342B (show.php)
RU (1) RU2017105849A (show.php)
SG (1) SG11201700506TA (show.php)
WO (1) WO2016014942A1 (show.php)
ZA (1) ZA201701341B (show.php)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112390883A (zh) 2013-12-17 2021-02-23 基因泰克公司 抗cd3抗体及使用方法
US11820832B2 (en) 2014-07-25 2023-11-21 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
EP3172236B1 (en) 2014-07-25 2020-09-30 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules
WO2018140026A1 (en) * 2017-01-27 2018-08-02 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules
CN107849145B (zh) 2015-06-16 2021-10-26 基因泰克公司 抗cd3抗体及其使用方法
CA3042435A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
US11046768B2 (en) * 2017-01-27 2021-06-29 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
BR112019021182A2 (pt) 2017-04-24 2020-06-02 Memorial Sloan Kettering Cancer Center Agentes de anticorpo anti-cd33
CN107854490A (zh) * 2017-09-26 2018-03-30 首都医科大学附属北京世纪坛医院 一种经修饰的t细胞及其应用
CN118772287A (zh) 2018-02-08 2024-10-15 豪夫迈·罗氏有限公司 双特异性抗原结合分子和使用方法
CA3093694A1 (en) * 2018-03-12 2019-09-19 Memorial Sloan Kettering Cancer Center Bispecific binding agents and uses thereof
IL319102A (en) * 2018-03-27 2025-04-01 Systimmune Inc Guidance and navigation control proteins and method for producing and using them
CN110357960A (zh) * 2018-04-10 2019-10-22 广州爱思迈生物医药科技有限公司 抗体及抗体改造方法
AU2019253232A1 (en) * 2018-04-13 2020-09-03 F. Hoffmann-La Roche Ag Her2-targeting antigen binding molecules comprising 4-1BBL
JP7539701B2 (ja) 2018-06-14 2024-08-26 バイオアトラ インコーポレイテッド 多重特異性抗体構造体
AU2019370339B2 (en) * 2018-11-01 2024-07-11 Shandong New Time Pharmaceutical Co., Ltd. Bispecific antibody and use thereof
CN111196856A (zh) * 2018-11-19 2020-05-26 三生国健药业(上海)股份有限公司 抗her2/pd1双特异性抗体
AU2019387482A1 (en) * 2018-11-30 2021-06-17 Memorial Sloan Kettering Cancer Center Heterodimeric tetravalency and specificity antibody compositions and uses thereof
US12351878B2 (en) * 2018-12-11 2025-07-08 The Translational Genomics Research Institute Identification of HER2 mutations in lung cancer and methods of treatment
AU2020225631A1 (en) 2019-02-22 2021-09-16 Memorial Sloan Kettering Cancer Center CD33 antibodies and methods of using the same to treat cancer
CN114341176A (zh) * 2019-04-08 2022-04-12 纪念斯隆凯特琳癌症中心 Cd19抗体及其使用方法
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
MX2021014193A (es) * 2019-05-23 2022-01-06 Velosbio Inc Moleculas de enlace biespecificas anti-ror1/anti-cd3.
CN114401744B (zh) * 2019-06-26 2024-11-05 纪念斯隆凯特琳癌症中心 用于治疗癌症的抗cd33抗体
AU2020403145B2 (en) 2019-12-13 2025-06-26 Genentech, Inc. Anti-Ly6G6D antibodies and methods of use
CA3182445A1 (en) 2020-06-11 2021-12-16 Francisco Leon Methods and compositions for preventing type 1 diabetes
US20230270857A1 (en) * 2020-07-28 2023-08-31 Memorial Sloan Kettering Cancer Center Compositions including ex vivo armed t cells with multi-specific antibodies and uses thereof
WO2022081443A2 (en) * 2020-10-12 2022-04-21 Memorial Sloan Kettering Cancer Center Anti-psma antibodies and uses thereof
IL302396A (en) 2020-11-04 2023-06-01 Genentech Inc Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies
TWI838660B (zh) 2020-11-04 2024-04-11 美商建南德克公司 以抗cd20/抗cd3雙特異性抗體和抗cd79b抗體藥物結合物治療的給藥方法
TWI888665B (zh) 2020-11-04 2025-07-01 美商建南德克公司 抗cd20/抗cd3雙特異性抗體之皮下給藥
TW202237827A (zh) 2020-12-03 2022-10-01 美商世紀治療股份有限公司 經基因工程改造之細胞及其用途
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
CA3202218A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
MX2023013363A (es) 2021-05-14 2023-11-27 Genentech Inc Metodos para el tratamiento de un trastorno proliferativo cd20 positivo con mosunetuzumab y polatuzumab vedotina.
AU2022324015A1 (en) * 2021-08-04 2024-02-15 Abpro Corporation Anti-her2 antibodies and uses thereof
CA3235788A1 (en) * 2021-10-20 2023-04-27 Nai-Kong V. Cheung Anti-tshr multi-specific antibodies and uses thereof
KR102803655B1 (ko) 2021-12-29 2025-05-08 건국대학교 글로컬산학협력단 개과 동물의 her1 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
KR102857671B1 (ko) 2021-12-29 2025-09-10 건국대학교 글로컬산학협력단 개과 동물의 her2 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
KR20250004727A (ko) 2022-04-13 2025-01-08 제넨테크, 인크. 모수네투주맙의 약학적 조성물 및 사용 방법
AU2024214000A1 (en) * 2023-02-04 2025-08-21 Imagion Biosystems, Inc. Method to assess nodal disease using iron oxide nanoparticles in magnetic resonance imaging
WO2025076473A1 (en) * 2023-10-06 2025-04-10 Fred Hutchinson Cancer Center Proteins bispecific to cd3 and nkg2dl and associated uses thereof
TW202532440A (zh) 2023-10-19 2025-08-16 美商建南德克公司 用於治療HER2陽性癌症的IL15/IL15Rα異二聚體FC融合蛋白及HER2xCD3雙特異性抗體之組合

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
SG155883A1 (en) 2004-06-03 2009-10-29 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
EP2155783B2 (en) 2007-04-03 2022-10-19 Amgen Research (Munich) GmbH Cross-species-specific cd3-epsilon binding domain
EP2403530B1 (en) 2009-02-27 2016-05-11 Massachusetts Institute of Technology Engineered proteins with high affinity for dota chelates
CA2800785C (en) 2010-05-27 2019-09-24 Genmab A/S Monoclonal antibodies against her2
KR101834026B1 (ko) * 2010-06-19 2018-03-02 메모리얼 슬로안-케터링 캔서 센터 항-gd2 항체
JP2014514314A (ja) * 2011-04-20 2014-06-19 ゲンマブ エー/エス Her2およびcd3に対する二重特異性抗体
HRP20191586T1 (hr) * 2011-05-08 2019-12-13 Legochem Biosciences Inc Konjugati agensa aktivni na proteine i postupak pripreme istih
ES2758884T3 (es) * 2011-06-24 2020-05-06 Stephen D Gillies Proteínas de fusión de inmunoglobulina a través de cadena ligera y métodos de uso de ellas
KR101653555B1 (ko) * 2011-11-02 2016-09-02 아지노모토 가부시키가이샤 단백질의 분비 생산 방법
EP2895203A4 (en) * 2012-06-15 2016-09-28 Imaginab Inc ANTIGENBINDING CONSTRUCTS FOR CD3
WO2014079000A1 (en) * 2012-11-21 2014-05-30 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody
PT3406633T (pt) * 2013-07-25 2022-05-04 Cytomx Therapeutics Inc Anticorpos multi-específicos, anticorpos ativáveis multi-específicos e métodos de utilização dos mesmos
EP3647324A1 (en) 2013-12-17 2020-05-06 F. Hoffmann-La Roche AG Methods of treating cancers using pd-1 axis binding antagonists and taxanes
EP3172236B1 (en) 2014-07-25 2020-09-30 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules
WO2018140026A1 (en) 2017-01-27 2018-08-02 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules
CA2976074A1 (en) 2015-02-09 2016-08-18 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
US11046768B2 (en) 2017-01-27 2021-06-29 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules

Similar Documents

Publication Publication Date Title
JP2017527274A5 (show.php)
RU2017105849A (ru) Биспецифические молекулы, связывающие her2 и cd3
Lou et al. Antibody variable region engineering for improving cancer immunotherapy
Godar et al. Therapeutic bispecific antibody formats: a patent applications review (1994-2017)
JP2020063262A5 (show.php)
Marvin et al. Recombinant approaches to IgG‐like bispecific antibodies
JP2017520575A5 (show.php)
Chen et al. Bispecific antibodies in cancer immunotherapy
JP2019524693A5 (show.php)
JP2013527761A5 (show.php)
FI3749346T3 (fi) Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät
JP2020533311A5 (ja) NKG2D、CD16およびNectin4に結合するタンパク質
JP2017504578A5 (show.php)
JP2020531438A5 (ja) Nkg2d、cd16、およびhla−eに結合するタンパク質
JP2020501531A5 (show.php)
JP2018503380A5 (show.php)
JP2018507188A5 (show.php)
RU2021110369A (ru) Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген
WO2013044215A4 (en) Vegf/dll4 binding agents and uses thereof
RU2016151645A (ru) Биспецифические гетеродимерные диантитела и их применение
RU2022102446A (ru) Биспецифические связывающие белки и пути их применения
HRP20200390T1 (hr) Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
JP2019500011A5 (show.php)
WO2018119118A4 (en) Lymphotoxin-beta receptor-binding agents, targeting antibodies, and uses thereof
IL276903B1 (en) Bispecific egfr/cd16 antigen-binding protein